Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Atezolizumab +/- Tiragolumab with Chemotherapy in Localized Esophageal and Gastroesophageal Adenocarcinoma
NCT03784326Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2019
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab and tiragolumab in esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma (2 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Pathological Complete Response up to 3 years. Started Feb 2019; status: active, not recruiting.
02
Drugs
atezolizumabtiragolumab
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03784326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03784326.